Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment
May 31 2019 - 8:30AM
via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces
the availability of a NetworkNewsAudio publication titled,
“Biotechs That Successfully Combat Cancer Could See Blockbuster
Returns.”
To hear the NetworkNewsWire Audio version, visit:
http://nnw.fm/LbI7g.
To read the full editorial, visit: http://nnw.fm/0CFNt.
Preliminary results show that
Oncoprex has the potential to become an effective add-on therapy
for the treatment of deadly non-small cell lung cancer.
Genprex Inc. (NASDAQ:GNPX) plans to expand the
current erlotinib-Oncoprex trial to multiple research centers and
conduct more new trials.
If Phase II results are as positive
as preliminary indications, it could spark a rally in the shares
and possibly even lure a large biotechnology or pharma company to
sign a high-value partnership with Genprex. Should such a strategic
partnership to commercialize Genprex’s technology transpire, it
could potentially generate enormous value for the company's
shareholders.
Without any of this in the bank,
Noble Financial has already pegged the stock to reach $5 a
share, nearly triple from today’s closing price. With such positive
preliminary results and blockbuster potential, it is possible that
Noble’s target price might even be low.
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex™ immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at www.genprex.com or follow Genprex on Twitter at
twitter.com/genprex, Facebook at facebook.com/genprexinc, and
LinkedIn at linkedin.com/company/genprex.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution,
allows you to sit back and listen to market updates, CEO interviews
and a Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024